These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 24859492)
1. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Damm O; Eichner M; Rose MA; Knuf M; Wutzler P; Liese JG; Krüger H; Greiner W Eur J Health Econ; 2015 Jun; 16(5):471-88. PubMed ID: 24859492 [TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151 [TBL] [Abstract][Full Text] [Related]
3. The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. Rose MA; Damm O; Greiner W; Knuf M; Wutzler P; Liese JG; Krüger H; Wahn U; Schaberg T; Schwehm M; Kochmann TF; Eichner M BMC Infect Dis; 2014 Jan; 14():40. PubMed ID: 24450996 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States. Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851 [TBL] [Abstract][Full Text] [Related]
5. Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. Gerlier L; Lamotte M; Grenèche S; Lenne X; Carrat F; Weil-Olivier C; Damm O; Schwehm M; Eichner M Appl Health Econ Health Policy; 2017 Apr; 15(2):261-276. PubMed ID: 27943165 [TBL] [Abstract][Full Text] [Related]
6. Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology Assessment. Andersohn F; Bornemann R; Damm O; Frank M; Mittendorf T; Theidel U GMS Health Technol Assess; 2014; 10():Doc03. PubMed ID: 25371764 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom. Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131 [TBL] [Abstract][Full Text] [Related]
8. Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany. Molnar D; Anastassopoulou A; Poulsen Nautrup B; Schmidt-Ott R; Eichner M; Schwehm M; Dos Santos G; Ultsch B; Bekkat-Berkani R; von Krempelhuber A; Van Vlaenderen I; Van Bellinghen LA Hum Vaccin Immunother; 2022 Nov; 18(5):2058304. PubMed ID: 35486410 [TBL] [Abstract][Full Text] [Related]
9. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland. Nagy L; Heikkinen T; Sackeyfio A; Pitman R Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657 [TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M Value Health; 2007; 10(2):98-116. PubMed ID: 17391419 [TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Influenza Vaccine for U.S. Children: Live Attenuated and Inactivated Influenza Vaccine. Shim E; Brown ST; DePasse J; Nowalk MP; Raviotta JM; Smith KJ; Zimmerman RK Am J Prev Med; 2016 Sep; 51(3):309-17. PubMed ID: 27079638 [TBL] [Abstract][Full Text] [Related]
12. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea. Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078 [TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands. de Boer PT; Nagy L; Dolk FCK; Wilschut JC; Pitman R; Postma MJ Value Health; 2021 Jan; 24(1):19-31. PubMed ID: 33431149 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England. Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M BMC Med; 2017 Sep; 15(1):166. PubMed ID: 28882149 [TBL] [Abstract][Full Text] [Related]
15. Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study. Simpson CR; Lone NI; Kavanagh K; Englishby T; Robertson C; McMenamin J; Wissman BV; Vasileiou E; Butler CC; Ritchie LD; Gunson R; Schwarze J; Sheikh A Health Technol Assess; 2020 Dec; 24(67):1-66. PubMed ID: 33256892 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach. Brogan AJ; Talbird SE; Davis AE; Thommes EW; Meier G Hum Vaccin Immunother; 2017 Mar; 13(3):533-542. PubMed ID: 27780425 [TBL] [Abstract][Full Text] [Related]
17. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy]. Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779 [TBL] [Abstract][Full Text] [Related]
18. Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium. Gerlier L; Lamotte M; Dos Santos Mendes S; Damm O; Schwehm M; Eichner M Paediatr Drugs; 2016 Aug; 18(4):303-18. PubMed ID: 27272706 [TBL] [Abstract][Full Text] [Related]
19. Live attenuated influenza vaccine for children. Drug Ther Bull; 2017 Oct; 55(10):114-117. PubMed ID: 29021248 [TBL] [Abstract][Full Text] [Related]
20. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model. Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]